Temi della conferenza Welcome to the 3rd In Vivo Cell Engineering and Gene Editing Summit!
As promising pre-clinical and proof of concept results continue to emerge, the pivotal shift from the 'dream' of in vivo cell engineering and gene editing is rapidly becoming a reality as numerous companies push towards the clinic.
Speakers: Adrian Bot, Chief Scientific Officer, Capstan Therapeutics, Cecile Bauche, Chief Scientific Officer, Alaya.bio, Colin Exline, Head of Gene Editing, Primera Therapeutics, and more